About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
European Heart Journal - Cardiovascular Pharmacotherapy
›
top-articles
European Heart Journal - Cardiovascular Pharmacotherapy
3.8
(top 10%)
impact factor
498
(top 50%)
papers
7.8K
(top 20%)
citations
40
(top 20%)
h
-index
3.9
(top 10%)
impact factor
733
all documents
8.7K
doc citations
58
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Gender differences in the effects of cardiovascular drugs
European Heart Journal - Cardiovascular Pharmacotherapy
2017
204
2
ESC Council on hypertension position document on the management of hypertensive emergencies
European Heart Journal - Cardiovascular Pharmacotherapy
2019
155
3
Statin therapy in COVID-19 infection
European Heart Journal - Cardiovascular Pharmacotherapy
2020
154
4
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology
European Heart Journal - Cardiovascular Pharmacotherapy
2018
113
5
Anticoagulation in COVID-19
European Heart Journal - Cardiovascular Pharmacotherapy
2020
105
6
PCSK9 and inflammation: a review of experimental and clinical evidence
European Heart Journal - Cardiovascular Pharmacotherapy
2019
104
7
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER
European Heart Journal - Cardiovascular Pharmacotherapy
2016
99
8
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
European Heart Journal - Cardiovascular Pharmacotherapy
2017
93
9
Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction
European Heart Journal - Cardiovascular Pharmacotherapy
2015
73
10
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives
European Heart Journal - Cardiovascular Pharmacotherapy
2017
73
11
A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
European Heart Journal - Cardiovascular Pharmacotherapy
2021
72
12
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
European Heart Journal - Cardiovascular Pharmacotherapy
2020
69
13
The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction
European Heart Journal - Cardiovascular Pharmacotherapy
2021
69
14
Melatonin has multiorgan effects
European Heart Journal - Cardiovascular Pharmacotherapy
2016
64
15
Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients
European Heart Journal - Cardiovascular Pharmacotherapy
2022
64
16
Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control study
European Heart Journal - Cardiovascular Pharmacotherapy
2017
63
17
Pharmacotherapy for coronary microvascular dysfunction
European Heart Journal - Cardiovascular Pharmacotherapy
2015
61
18
A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease
European Heart Journal - Cardiovascular Pharmacotherapy
2016
61
19
Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy
2019
61
20
The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study
European Heart Journal - Cardiovascular Pharmacotherapy
2021
61
21
Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial
European Heart Journal - Cardiovascular Pharmacotherapy
2015
59
22
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
European Heart Journal - Cardiovascular Pharmacotherapy
2020
59
23
Cardiovascular safety of anti-diabetic drugs
European Heart Journal - Cardiovascular Pharmacotherapy
2016
56
24
New oral anticoagulants: a practical guide for physicians
European Heart Journal - Cardiovascular Pharmacotherapy
2015
54
25
The current role and future prospects of D-dimer biomarker
European Heart Journal - Cardiovascular Pharmacotherapy
2016
52
26
Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
European Heart Journal - Cardiovascular Pharmacotherapy
2020
52
27
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality
European Heart Journal - Cardiovascular Pharmacotherapy
2020
51
28
Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation
European Heart Journal - Cardiovascular Pharmacotherapy
2021
51
29
Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries
European Heart Journal - Cardiovascular Pharmacotherapy
2016
50
30
Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
European Heart Journal - Cardiovascular Pharmacotherapy
2017
50
31
Left ventricular thrombosis: new perspectives on an old problem
European Heart Journal - Cardiovascular Pharmacotherapy
2021
50
32
Interleukin-1 blockade for the treatment of pericarditis
European Heart Journal - Cardiovascular Pharmacotherapy
2018
49
33
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
European Heart Journal - Cardiovascular Pharmacotherapy
2018
48
34
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
European Heart Journal - Cardiovascular Pharmacotherapy
2020
48
35
Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT
2
R
2
score
European Heart Journal - Cardiovascular Pharmacotherapy
2015
47
36
Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future
European Heart Journal - Cardiovascular Pharmacotherapy
2017
47
37
P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
European Heart Journal - Cardiovascular Pharmacotherapy
2016
46
38
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
European Heart Journal - Cardiovascular Pharmacotherapy
2019
46
39
An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome
European Heart Journal - Cardiovascular Pharmacotherapy
2020
46
40
Association between renin–angiotensin system inhibitors and COVID-19 complications
European Heart Journal - Cardiovascular Pharmacotherapy
2021
46
41
Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists
European Heart Journal - Cardiovascular Pharmacotherapy
2017
45
42
Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients
European Heart Journal - Cardiovascular Pharmacotherapy
2021
45
43
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
European Heart Journal - Cardiovascular Pharmacotherapy
2022
45
44
Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge
European Heart Journal - Cardiovascular Pharmacotherapy
2019
44
45
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors
European Heart Journal - Cardiovascular Pharmacotherapy
2017
43
46
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin–angiotensin system
European Heart Journal - Cardiovascular Pharmacotherapy
2020
42
47
Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database
European Heart Journal - Cardiovascular Pharmacotherapy
2021
42
48
The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent
European Heart Journal - Cardiovascular Pharmacotherapy
2016
41
49
Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
European Heart Journal - Cardiovascular Pharmacotherapy
2020
41
50
Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)
European Heart Journal - Cardiovascular Pharmacotherapy
2016
40
site/software ©
exaly
; All materials licenced under
CC by-SA
.